Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer

被引：1
|
作者：
Oguz, Arzu [1 ]
Keskin, Gul Sema [1 ]
Colak, Dilsen [1 ]
Altundag, Ozden [1 ]
Akcali, Zafer [1 ]
机构：
[1] Baskent Univ, Bahcelievler Ankara, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 06期
关键词：
ADJUVANT TRASTUZUMAB; RISK; CM;
D O I：
10.1200/JCO.2015.63.8411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：639 / +
页数：3
相关论文
共 50 条
  • [1] Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer Reply
    O'Sullivan, Ciara C.
    Holmes, Eileen
    Campbell, Christine
    Bradbury, Ian
    Zujewski, Jo Anne
    Gelber, Richard D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 640 - +
  • [2] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    [J]. PLOS ONE, 2019, 14 (06):
  • [3] Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer
    Shi, Qiyun
    Wang, Ju
    Ai, Xiang
    Xuhong, Juncheng
    Ma, Dandan
    Zhang, Yi
    Qi, Xiaowei
    Jiang, Jun
    [J]. GLAND SURGERY, 2021, 10 (07) : 2255 - +
  • [4] Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer
    Sharifi, Marina
    Wisinski, Kari B.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 482 - 492
  • [5] Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
    Cadoo, Karen A.
    Morris, Patrick G.
    Cowell, Elizabeth P.
    Patil, Sujata
    Hudis, Clifford A.
    McArthur, Heather L.
    [J]. CLINICAL BREAST CANCER, 2016, 16 (06) : 487 - 493
  • [6] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    [J]. BREAST DISEASES, 2015, 26 (04): : 285 - 287
  • [7] Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
    Tolaney, Sara M.
    Barry, William T.
    Dang, Chau T.
    Yardley, Denise A.
    Moy, Beverly
    Marcom, P. Kelly
    Albain, Kathy S.
    Rugo, Hope S.
    Ellis, Matthew
    Shapira, Iuliana
    Wolff, Antonio C.
    Carey, Lisa A.
    Overmoyer, Beth A.
    Partridge, Ann H.
    Guo, Hao
    Hudis, Clifford A.
    Krop, Ian E.
    Burstein, Harold J.
    Winer, Eric P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 134 - 141
  • [8] Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
    Cochereau, D.
    Cottu, P.
    [J]. ONCOLOGIE, 2015, 17 (04) : 194 - 196
  • [9] Systemic therapy for HER2-positive early-stage breast cancer
    Mathew, Aju
    Romond, Edward H.
    [J]. CURRENT PROBLEMS IN CANCER, 2016, 40 (2-4) : 106 - 116
  • [10] Risk of Recurrence in Early-Stage, HER2-Positive Breast Cancer
    Isaacs, Claudine
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (08) : 3 - 6
12345